Clinical Trial Update: Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of imatinib mesylate in unresectable recurrent glioblastoma expressing PDGFR was terminated; the study status is TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED